C22orf15

Across TCGA pan-cancer cohorts, C22orf15 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated C22orf15 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher C22orf15 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C22orf15 expression acts as an unfavorable survival marker.

HNSC and SKCM are the cancer types where C22orf15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.087	0.710	<.001	36	view →
SKCM	DFS	Median	All	0.009	0.738	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

C22orf15–HNSC (DFS)

Open the HNSC breakdown →